Clinical trials: Skin Cancer Face
ACTINIC KERATOSIS
An Equivalence Study of Generic Ingenol Mebutate Gel 0.015% and Picato Gel 0.015% in Subjects With Actinic Keratosis
The objective of this study was to evaluate the safety and therapeutic equivalence of generic ingenol mebutate gel, 0.015% to Picato gel, 0.015% by establishing the therapeutic comparability of the two active products and the…
- Trial name
- NCT03200912
- Testing
- Ingenol Mebutate (Picato®), Generic Ingenol Mebutate, Vehicle Foam
- Where
- 23 sites in United States
- Volunteers
- 507 people
- Sponsor
- Actavis Inc.
Actinic Keratosis
Efficacy and Safety of LEO 43204 in the Field Treatment of Actinic Keratosis on Face or Chest including12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment
- Trial name
- NCT02549339
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 383 people
- Sponsor
- LEO Pharma
Actinic Keratosis
A Study of Increasing Strengths, Safety and Efficacy of Two Formulas of LEO 43204 on the Face or the Chest in Patients With Actinic Keratosis
Part 1: To identify Maximum Tolerated Dose (MTD) levels of two formulations of LEO 43204 after once daily treatment for two consecutive days Part 2: To evaluate efficacy of two formulations of LEO 43204 in two doses after once…
- Trial name
- NCT01922050
- Testing
- LEO 43204 Formulation 1, LEO 43204 Formulation 2, LEO 43204 Formulation 1 Dose X
- Where
- 25 sites in United States, Canada
- Volunteers
- 320 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest
The objective of the trial is to investigate efficacy and safety of ingenol mebutate gel for actinic keratosis applied to large treatment areas once daily for three consecutive days on face, scalp or chest.
- Trial name
- NCT02361216
- Testing
- Ingenol Mebutate, Vehicle
- Where
- United States
- Volunteers
- 729 people, healthy volunteers welcome
- Sponsor
- LEO Pharma
Actinic Keratosis (AK)
Risk of Squamous Cell Carcinoma on Skin Areas Treated With Ingenol Mebutate Gel, 0.015% and Imiquimod Cream, 5%
The purpose of the study is to compare the risk of developing squamous skin cancer (SCC) or other types of cancer after treatment of AKs with ingenol mebutate gel or imiquimod cream.
- Trial name
- NCT01926496
- Testing
- Ingenol Mebutate Gel, 0.015%, Imiquimod Cream, 5%
- Where
- 46 sites in France, Germany and 1 more
- Volunteers
- 485 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
A Study to Assess Recurrence of Actinic Keratosis in Participants Treated With Methyl Aminolevulinate Hydrochloride Cream or Vehicle Cream Who Achieved Complete Response to Treated Lesions in Earlier Study
The primary purpose for this study is to assess recurrence of Actinic Keratosis in participants achieving complete response treated in earlier study.
- Trial name
- NCT04269395
- Testing
- MAL Cream, Vehicle cream
- Where
- 53 sites in United States, Puerto Rico
- Volunteers
- 125 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Controlled Study of the Occurrence of Actinic Keratosis on the Face After Cryotherapy + Aminolevulinic Acid (ALA) Photodynamic Therapy
The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy.
- Trial name
- NCT02239679
- Testing
- Aminolevulinic Acid, Topical Solution Vehicle, BLU-U
- Where
- 8 sites in United States
- Volunteers
- 166 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Actinic Keratosis (AK)
A Study to Evaluate Two Concentrations of DFD-07 Cream, in Subjects With Actinic Keratosis (AK) of the Face and/or Scalp Over a 12-week Treatment Period
Once or twice daily 12 week treatment in patients with Actinic Keratosis randomized to treatment in one of four arms.
- Trial name
- NCT03116698
- Testing
- Low dose DFD07 once daily, High dose DFD07 once daily, High dose DFD07 twice daily
- Where
- 20 sites in United States
- Volunteers
- 240 people
- Sponsor
- Dr. Reddy's Laboratories Limited
Actinic Keratosis
A Multi-Center Study to Evaluate the Efficacy and Safety of PEP005 (Ingenol Mebutate) Gel, When Used to Treat Actinic Keratoses on the Head (Face or Scalp)
This Phase III study is designed to assess the efficacy and safety of PEP005 Gel, 0.015% when applied to an area of skin containing 4-8 AK lesions on the face or scalp.
- Trial name
- NCT00915551
- Testing
- PEP005 (Ingenol Mebutate) gel, 0.015%, Vehicle Gel
- Where
- 21 sites in United States, Australia
- Volunteers
- 278 people
- Sponsor
- Peplin
Actinic Keratosis
Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Face or Chest Including 12-month Follow-up
The objective of the trial is to compare the short term efficacy of LEO 43204 gel with vehicle gel in AK on face or chest when applied topically once daily for 3 consecutive days as field treatment.
- Trial name
- NCT02547233
- Testing
- LEO 43204 gel, Vehicle gel
- Where
- United States
- Volunteers
- 437 people
- Sponsor
- LEO Pharma
Keratosis, Actinic
Patient and Clinician Reported Outcomes for Tirbanibulin Effectiveness and Safety in Actinic Keratosis
The purpose of the study is to evaluate patient reported outcomes (PROs) in terms of health-related quality of life (HRQoL) among subjects with actinic keratosis (AK).
- Trial name
- PROAK (NCT05260073)
- Testing
- Tirbanibulin
- Where
- United States
- Volunteers
- 300 people
- Sponsor
- Almirall, S.A.
Actinic Keratoses
The Efficacy and Tolerability of Oleogel-S-10 in Patients With Actinic Keratoses
In this study the impact of Oleogel-S-10 versus placebo on actinic keratoses over a treatment period of 3 months will be tested. Additionally, once and twice daily applications are tested.
- Trial name
- NCT00786994
- Testing
- Oleogel-S10 100 mg/g
- Where
- 6 sites in Germany, Greece
- Volunteers
- 165 people
- Sponsor
- Birken AG
Actinic Keratoses
A Multi-Center Study to Evaluate the Efficacy and Safety of KX2-391 Ointment 1% on AK on Face or Scalp
This Phase III study is designed to evaluate the efficacy and safety of KX2-391 Ointment in adult participants when applied to an area of skin containing 4-8 stable, clinically typical Actinic Keratosis (AK) lesions on the face…
- Trial name
- AK003 (NCT03285477)
- Testing
- KX2-391 Ointment 1%
- Where
- 30 sites in United States
- Volunteers
- 351 people
- Sponsor
- Almirall, S.A.
Actinic Keratoses
PRO With Luxerm® in the Field Treatment of Thin and Non-hyperkeratotic Non-pigmented AK
Interventional open label prospective and multicentre study conducted in Germany in subjects with thin or non-hyperkeratotic and non-pigmented multiple AKs in one anatomical area on the face (e.g., forehead or cheek or chin)…
- Trial name
- SESAME 2 (NCT03511326)
- Testing
- Methyl Aminolaevulinate 16% Cream
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Galderma R&D
Actinic Keratosis
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
- Trial name
- NCT02838628
- Testing
- 50 mg of KX2-391 Ointment 1%
- Where
- 16 sites in United States
- Volunteers
- 168 people
- Sponsor
- Almirall, S.A.
Actinic Keratosis
Safety and Efficacy of Ingenol Mebutate Once Daily for 2 or 3 Consecutive Days in Subjects With Actinic Keratosis
To identify the Maximum Tolerated Dose levels of ingenol mebutate gel after once daily treatment for 2 or 3 consecutive days and to evaluate efficacy of ingenol mebutate gel in different doses after once daily treatment for 2 or…
- Trial name
- NCT01820260
- Testing
- Ingenol mebutate gel
- Where
- United States
- Volunteers
- 395 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Ingenol Mebutate Gel, 0.015% Repeat Use for Multiple Actinic Keratoses on Face and Scalp
The purpose of the study is to demonstrate that ingenol mebutate gel is efficacious in treating Actinic Keratoses (AKs) present 8 weeks after initial field treatment or emerging in a previously cleared field.
- Trial name
- NCT01600014
- Testing
- Ingenol mebutate gel, 0.015%, Vehicle gel
- Where
- 13 sites in Australia, Canada and 3 more
- Volunteers
- 463 people
- Sponsor
- LEO Pharma
Actinic Keratosis
Microneedle Lesion Preparation Prior to Aminolevulinic Acid Photodynamic Therapy (ALA-PDT) for AK on Face
The purpose of this study is to determine the viability of microneedle lesion preparation (MN) to enhance treatment benefit when performed prior to ALA PDT to an actinic keratosis (AK) field on the face.
- Trial name
- NCT02632110
- Testing
- ALA, Topical Solution Vehicle, IBL 10 mW
- Where
- 8 sites in United States
- Volunteers
- 137 people
- Sponsor
- DUSA Pharmaceuticals, Inc.
Cushing's Syndrome
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Participants in study C-1073-400 (NCT00569582) will be invited to participate in this extension study to examine the long term safety of mifepristone in the treatment of the signs and symptoms of endogenous Cushing's syndrome.
- Trial name
- NCT00936741
- Testing
- mifepristone
- Where
- 15 sites in United States
- Volunteers
- 30 people
- Sponsor
- Corcept Therapeutics
Breast Cancer
Comparison Trial of Letrozole to Anastrozole in the Adjuvant Treatment of Postmenopausal Women With Hormone Receptor and Node Positive Breast Cancer
Eligible patients will be post-menopausal hormone receptor- and lymph node-positive females who recently underwent primary surgery for breast cancer.
- Trial name
- FACE (NCT00248170)
- Testing
- Letrozole, Anastrozole
- Where
- 259 sites in United States, Australia and 18 more
- Volunteers
- 4,172 people
- Sponsor
- Novartis Pharmaceuticals